Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China-Reference-Cited by-同舟云学术

Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China

Published:2017-05 Issue:19 Volume:96 Page:e6830
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Li Zhanyi,Zhang Ying,Liu Ying,Shao Xiaoqiong,Luo QiuMin,Cai Qingxian,Zhao Zhixin

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference40 articles.

1. IDX184 in combination with pegylated interferon-alpha2a and ribavirin for 2 weeks in treatment-nai[Combining Diaeresis]ve patients with chronic hepatitis C;Lalezari;Antivir Ther,2013

2. Effect of drug-resistance mutations on antiviral agents in HCV patients;Liu;Antivir Ther,2016

3. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose;Hadziyannis;Ann Intern Med,2004

4. The hepatitis C virus life cycle as a target for new antiviral therapies;Pawlotsky;Gastroenterology,2007

5. Directly acting antivirals against hepatitis C virus;Soriano;J Antimicrob Chemother,2011

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emergence of resistance against direct acting antivirals in chronic HCV patients: A real-world study;Saudi Journal of Biological Sciences;2021-12

2. Distribution of naturally -occurring NS5B resistance-associated substitutions in Egyptian patients with chronic Hepatitis C;PLOS ONE;2021-04-15

3. Major mutations in the NS3 gene region of hepatitis C virus related to the resistance to direct acting antiviral drugs: a systematic review;VirusDisease;2020-08-04

4. The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan;Biomedical Journal;2020-08

5. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil;Clinics and Research in Hepatology and Gastroenterology;2020-06